Bank of America Corp DE Sells 79,254 Shares of Harrow, Inc. (NASDAQ:HROW)

Bank of America Corp DE lowered its position in Harrow, Inc. (NASDAQ:HROW - Free Report) by 62.6% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 47,392 shares of the company's stock after selling 79,254 shares during the period. Bank of America Corp DE owned 0.13% of Harrow worth $1,590,000 as of its most recent filing with the SEC.

Other institutional investors also recently modified their holdings of the company. Freestone Grove Partners LP bought a new position in Harrow during the fourth quarter worth $390,000. Northern Trust Corp grew its holdings in Harrow by 7.5% during the 4th quarter. Northern Trust Corp now owns 319,084 shares of the company's stock worth $10,705,000 after acquiring an additional 22,266 shares during the period. Aquatic Capital Management LLC acquired a new stake in Harrow during the 4th quarter worth about $78,000. Price T Rowe Associates Inc. MD raised its position in shares of Harrow by 8.1% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 19,076 shares of the company's stock worth $640,000 after acquiring an additional 1,428 shares in the last quarter. Finally, Harvest Investment Services LLC acquired a new position in shares of Harrow in the 4th quarter valued at about $773,000. 72.76% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on the company. B. Riley decreased their target price on Harrow from $69.00 to $65.00 and set a "buy" rating for the company in a research note on Tuesday, April 1st. HC Wainwright increased their price target on Harrow from $57.00 to $60.00 and gave the stock a "buy" rating in a report on Monday, May 12th.

Harrow Stock Up 3.0%

Shares of NASDAQ HROW traded up $0.87 during trading on Friday, hitting $29.59. 333,179 shares of the company traded hands, compared to its average volume of 497,990. The business's fifty day moving average is $25.36 and its 200 day moving average is $30.16. Harrow, Inc. has a fifty-two week low of $16.87 and a fifty-two week high of $59.23. The company has a debt-to-equity ratio of 3.23, a quick ratio of 1.44 and a current ratio of 1.55. The firm has a market capitalization of $1.09 billion, a price-to-earnings ratio of -31.48 and a beta of 0.41.

Harrow (NASDAQ:HROW - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported ($0.38) EPS for the quarter, missing the consensus estimate of $0.02 by ($0.40). Harrow had a negative net margin of 19.75% and a negative return on equity of 45.57%. The firm had revenue of $47.83 million for the quarter, compared to the consensus estimate of $57.00 million. Equities research analysts predict that Harrow, Inc. will post -0.53 earnings per share for the current fiscal year.

Harrow Company Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.